| |
| |
|
| Insider
Information: |
Morrow George J |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
164,177 |
|
|
Indirect Shares
|
5,990 |
|
|
| Direct
Value |
$41,537,825 |
|
|
|
Indirect Value
|
$1,695,313 |
|
|
| Total
Shares |
170,167 |
|
|
| Total
Value |
$43,233,138 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 18.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
Exe VP, Global Commerc... |
2010-04-29 |
130,488 |
2010-04-29 |
2,717 |
Premium* |
|
|
Align Technology Inc |
ALGN |
|
2024-05-17 |
2,143 |
2024-05-17 |
3,273 |
Premium* |
|
|
Human Genome Sciences Inc |
HGSI |
Director |
2012-07-30 |
0 |
2011-05-12 |
0 |
Premium* |
|
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
Director |
2015-05-21 |
27,347 |
2012-10-15 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
4,199 |
2024-03-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-14 |
4 |
OE |
$39.79 |
$1,591,600 |
D/D |
40,000 |
20,000 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-03-14 |
4 |
AS |
$139.41 |
$5,576,710 |
D/D |
(40,000) |
0 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,199 |
4,199 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2011-08-05 |
4 |
B |
$15.79 |
$157,900 |
D/D |
10,000 |
12,500 |
2.39 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
– • – |
2012-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
15,000 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-30 |
4 |
D |
$14.25 |
$59,366 |
D/D |
(4,166) |
10,834 |
0 |
- |
|
| HGSI |
Human Genome Sciences Inc |
Director |
• • – |
2012-07-30 |
4 |
D |
$14.25 |
$154,385 |
D/D |
(10,834) |
0 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2012-10-15 |
4 |
B |
$0.01 |
$64 |
D/D |
6,394 |
6,394 |
2.31 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2013-05-23 |
4 |
B |
$0.01 |
$60 |
D/D |
5,953 |
12,347 |
2.31 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
19,847 |
0 |
- |
|
| FRTX |
Fresh Tracks Therapeutics... |
Director |
– • – |
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
27,347 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2004-11-23 |
4 |
S |
$59.55 |
$3,575,131 |
D/D |
(59,998) |
10,000 |
|
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2004-11-23 |
4 |
OE |
$38.36 |
$2,301,523 |
D/D |
59,998 |
69,998 |
|
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2005-07-25 |
4 |
S |
$80.93 |
$24,604,492 |
D/D |
(303,335) |
10,000 |
|
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2005-07-25 |
4 |
OE |
$38.36 |
$17,684,522 |
D/D |
303,335 |
313,335 |
|
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2007-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
62,698 |
72,698 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2007-05-11 |
4 |
D |
$54.25 |
$1,486,504 |
D/D |
(27,401) |
45,297 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2007-12-07 |
4 |
B |
$69.97 |
$141,719 |
I/I |
2,025 |
2,025 |
1.99 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2007-12-10 |
4 |
OE |
$38.36 |
$100,081 |
D/D |
2,609 |
47,906 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
59,906 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
60,658 |
120,564 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-05-12 |
4 |
D |
$41.86 |
$1,125,657 |
D/D |
(26,891) |
93,673 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-10-24 |
4 |
S |
$54.48 |
$3,126,641 |
D/D |
(57,394) |
93,673 |
0 |
- |
|
| AMGN |
Amgen Inc |
Exe VP, Global Commercial Ops |
• – – |
2008-10-24 |
4 |
OE |
$38.36 |
$2,201,634 |
D/D |
57,394 |
151,067 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
